Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Leadership changes at Roche

<< Previous

Bullboard Posts

Next >>

Comment by PeteZerriaon Dec 12, 2022 2:28pm

179 Views

Post# 35166670

RE:RE:Leadership changes at Roche

Sounds like internal conflict came to a head at Roche.
"Let's focus on oncology and find some cures for cancer"
"No, let's spend hundreds of millions testing this Alzheimer's drug"
"Oh cr&p the the Alzheimer's drug doesn't work, who do we blame?"
"Bill, you're fired"
"OK, so what we need to do now is expand our oncology pipeline and buy ____"

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute